|
Bioxel manufactures and markets taxane active pharmaceutical ingredients (APIs) and develops innovative new taxane-based chemotherapeutic drugs. Taxanes include paclitaxel and docetaxel, two active pharmaceutical ingredients (APIs) widely used in cancer treatment. Together these taxane based drugs accounted for worldwide sales of approximately US$4 billion in 2006.
Bioxel has manufactured and distributed natural paclitaxel for international pharmaceutical companies since 2004. Bioxel's paclitaxel is used in second-generation drugs now in advanced stages of clinical development and in generic drug products currently marketed in North America and Europe.
In 2005, Bioxel filed patents for the semi-synthesis of paclitaxel and docetaxel from the taxane starting materials 9-DHB and 10-DAB. The Corporation has built a large inventory of 9-DHB from which it intends to produce its new semi-synthetic taxanes. Drawing on solid intellectual property and this unique access to 9-DHB, Bioxel is ideally positioned to compete in the paclitaxel market and to tap the potential of the docetaxel market that will open up to generic competition starting in 2008.
|
